Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Succinate"

From Bioblast
 
(33 intermediate revisions by 10 users not shown)
Line 1: Line 1:
{{MitoPedia
{{MitoPedia
|abbr=S
|abbr=S
|description='''Succinate<sup>2-</sup>''' is formed in the [[TCA cycle]], and is a substrate of [[CII]], reacting to fumarate and feeding electrons into the [[Q-junction]]. Succinate (CII-linked) and NADH (CI-linked) provide convergent electron entries into the Q-junction. Succinate is transported across the inner mitochondrial membrane by the [[dicarboxylate carrier]].
|description=[[File:Succinic_acid.jpg|left|100px|Succinic acid]]
|info=[http://www.oroboros.at/?Gnaiger_2012_MitoPathways Gnaiger 2012 MitoPathways]
'''Succinic acid''', C<sub>4</sub>H<sub>6</sub>O<sub>4</sub>, (butanedioic acid) is a dicarboxylic acid which occurs under physiological conditions as the anion '''succinate<sup>2-</sup>, S''', with ''p''K<sub>a1</sub> = 4.2 and ''p''K<sub>a2</sub> = 5.6. Succinate is formed in the [[TCA cycle]], and is a substrate of [[Complex II |CII]], reacting to [[fumarate]] and feeding electrons into the [[Q-junction]]. Succinate (CII-linked) and NADH (CI-linked) provide convergent electron entries into the Q-junction. Succinate is transported across the inner mt-membrane by the [[dicarboxylate carrier]]. The plasma membrane of many cell types is impermeable for succinate (but see [[Zhunussova 2015 Am J Cancer Res]] for an exception). Incubation of mt-preparations by succinate alone may lead to accumulation of [[oxaloacetate]], which is a potent inhibitor of Complex II (compare [[Succinate and rotenone]]). High activities of mt-[[Malic enzyme]] (mtME) prevent accumulation of oxaloacetate in incubations with succinate without rotenone.
|type=Respiration
|info=[[Gnaiger 2020 BEC MitoPathways]], [[Tretter 2016 Biochim Biophys Acta]]
}}
}}
{{MitoPedia methods|type=Respiration
__TOC__
}}
 
{{MitoPedia topics
[[File:S.jpg|400px|thumb|Succinate, S. From [[Gnaiger 2020 BEC MitoPathways]].]]
|mitopedia topic=Substrate and metabolite
== Application in [[HRR]] ==
|type=Respiration
{{Chemical_description
}}
|abbr=S
== Application in [[HRR]] ==
|trivial name=Succinate
|complete name=Sodium succinate dibasic hexahydrate
|chem formula= C<sub>4</sub>H<sub>4</sub>0<sub>4</sub>Na<sub>2</sub> * 6H<sub>2</sub>O
 
|molar mass=270.1
 
|vendor=Sigma-Aldrich
|product number=S2378
|store at=RT
|sensitivity=
|cas=6106-21-4
|h statements=
 
|h info=
}}<!--:::'''S: Succinate''' (Succinate disodium salt, hexahydrate, C<sub>4</sub>H<sub>4</sub>0<sub>4</sub>Na<sub>2</sub> * (H<sub>2</sub>O)<sub>6</sub>; Sigma S 2378, 100 g, store at RT; M = 270.1 g·mol<sup>-1</sup>)-->
:::: In the absence of CI-linked substrates, add the CI-inhibitor [[rotenone]] before addition of succinate, to avoid accumulation of [[oxaloacetate]] with subsequent inhibition of [[succinate dehydrogenase]]. See: [[Succinate and rotenone]].
:::: When keeping the succinate stock solution on ice, check for complete solubilization of succinate and warm the stock solution in your hands if necessary.
 
 
:::: '''Preparation of 1 M stock solution:'''
 
::::# Weight 1.3505 g of succinate and dissolve in 3 mL H<sub>2</sub>O;
::::# Check pH and adjust to 7.0 if necessary with 1 M HCl (about 65 µL will be needed);
::::# Transfer to 5 mL volumetric glass flask and adjust the final volume to 5 mL;
::::# Divide into 0.5 mL portions;
::::# Store frozen at -20 °C.


'''S: Succinate''' (Succinate disodium salt, hexahydrate, C<sub>4</sub>H<sub>4</sub>0<sub>4</sub>Na<sub>2</sub> * (H<sub>2</sub>O)<sub>6</sub>); Sigma S 2378, 100 g, store at R.T.; FW = 270.1
:::» '''O2k manual titrations''' [[MiPNet09.12 O2k-Titrations]]


'''Preparation of 1 M stock solution''' (dissolved in H<sub>2</sub>O):  
::::* Titration volume ('''2-mL O2k-chamber'''): 20 µL using a 50 µL Hamilton syringe.
::::* Titration volume ('''0.5-mL O2k-chamber'''): 5 µL using a 25 µL Hamilton syringe
::::* Final concentration: 10 mM. Note: The concentration of succinate may be increased up to 50 mM after [[rotenone]] to compensate for the inhibitory effect of [[malate]].   


::1) Weigh 1.3505 g of succinate and dissolve in 3 ml H<sub>2</sub>O.
::2) Check pH and adjust to 7.0 if necessary with 1 N HCl (usually the pH is 7 without any adjustment).
::3) Transfer to 5 ml volumetric glass flask and adjust the final volume to 5 ml.
::4) Divide into 0.2 ml portions.
::5) Store frozen at -20 °C.




'''Oxygraph-2k Manual Titrations:''' [[MiPNet09.12]]  
== [[SUITbrowser]] question: Succinate pathway ==
:::: The [https://suitbrowser.oroboros.at/ SUITbrowser] can be used to find the best SUIT protocols to analyze the succinate pathway, among other research questions.


::* In the absence of CI-linked substrates, add the CI-inhibitor [[rotenone]] before addition of succinate, to avoid accumulation of [[oxaloacetate]] with subsequent inhibition of succiante dehydrogenase.
{{MitoPedia topics
::* When keeping the succinate stock solution on ice, check for complete solubilization of succinate and warm in your hands if necessary.
|mitopedia topic=Substrate and metabolite
::* Titration volume: 20 µl using a 50 µl syringe (2 ml O2k-chamber).
}}
::* Final concentration: 10 mM.

Latest revision as of 15:06, 17 December 2022


high-resolution terminology - matching measurements at high-resolution


Succinate

Description

Succinic acid

Succinic acid, C4H6O4, (butanedioic acid) is a dicarboxylic acid which occurs under physiological conditions as the anion succinate2-, S, with pKa1 = 4.2 and pKa2 = 5.6. Succinate is formed in the TCA cycle, and is a substrate of CII, reacting to fumarate and feeding electrons into the Q-junction. Succinate (CII-linked) and NADH (CI-linked) provide convergent electron entries into the Q-junction. Succinate is transported across the inner mt-membrane by the dicarboxylate carrier. The plasma membrane of many cell types is impermeable for succinate (but see Zhunussova 2015 Am J Cancer Res for an exception). Incubation of mt-preparations by succinate alone may lead to accumulation of oxaloacetate, which is a potent inhibitor of Complex II (compare Succinate and rotenone). High activities of mt-Malic enzyme (mtME) prevent accumulation of oxaloacetate in incubations with succinate without rotenone.

Abbreviation: S

Reference: Gnaiger 2020 BEC MitoPathways, Tretter 2016 Biochim Biophys Acta

Succinate, S. From Gnaiger 2020 BEC MitoPathways.

Application in HRR

S: Succinate (Sodium succinate dibasic hexahydrate; C4H404Na2 * 6H2O), Sigma-Aldrich: S2378, store at RT, CAS: 6106-21-4, M = 270.1 g·mol-1
In the absence of CI-linked substrates, add the CI-inhibitor rotenone before addition of succinate, to avoid accumulation of oxaloacetate with subsequent inhibition of succinate dehydrogenase. See: Succinate and rotenone.
When keeping the succinate stock solution on ice, check for complete solubilization of succinate and warm the stock solution in your hands if necessary.


Preparation of 1 M stock solution:
  1. Weight 1.3505 g of succinate and dissolve in 3 mL H2O;
  2. Check pH and adjust to 7.0 if necessary with 1 M HCl (about 65 µL will be needed);
  3. Transfer to 5 mL volumetric glass flask and adjust the final volume to 5 mL;
  4. Divide into 0.5 mL portions;
  5. Store frozen at -20 °C.
» O2k manual titrations MiPNet09.12 O2k-Titrations
  • Titration volume (2-mL O2k-chamber): 20 µL using a 50 µL Hamilton syringe.
  • Titration volume (0.5-mL O2k-chamber): 5 µL using a 25 µL Hamilton syringe
  • Final concentration: 10 mM. Note: The concentration of succinate may be increased up to 50 mM after rotenone to compensate for the inhibitory effect of malate.


SUITbrowser question: Succinate pathway

The SUITbrowser can be used to find the best SUIT protocols to analyze the succinate pathway, among other research questions.


MitoPedia topics: Substrate and metabolite